Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
Status:
Completed
Trial end date:
2021-04-10
Target enrollment:
Participant gender:
Summary
This is a prospective randomized phase II trial was done in clinical oncology department at
Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of
chemotherapy in the first line for treatment of metastatic colorectal carcinoma by adding
third agent to standard doublet regimen on oncological outcomes & assess tolerance to the
intensified treatment